CoChat
Sign Up
Cited by 324Thyroid Disorders and TreatmentsThyroid and Parathyroid SurgeryThyroid Cancer Diagnosis and Treatment

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Levothyroxine Therapy in Patients with Thyroid Disease

Mandel, Susan J., Brent, Gregory A., Larsen, P. Reed·1993·Annals of Internal Medicine
DOI 10.7326/0003-4819-119-6-199309150-00009
Open this paper in CoChat — free account

Abstract

PURPOSE: To review the indications for and the proper monitoring of levothyroxine therapy in patients with thyroid disease. DATA SOURCES: Relevant English language articles published from 1966 to 1992 were identified through a MEDLINE search and manual searches of both identified articles and selected endocrinology texts. STUDY SELECTION: Studies, case reports, and review articles that contained data on the pathophysiologic aspects of relevant thyroid disorders and on the pharmacologic aspects of, indications for, and administration of levothyroxine therapy. DATA EXTRACTION: Data on the epidemiology, clinical manifestations, complications, and treatment of thyroid disorders were analyzed with respect to patient selection, methods, diagnostic criteria, and conclusions. These data were used to develop a rational approach to the management of such patients. RESULTS OF DATA SYNTHESIS: Levothyroxine is a reliable and commonly prescribed drug to treat thyroid disease, but excessive dosage may have adverse effects. In patients with hypothyroidism, levothyroxine is used as replacement therapy. For most patients, therapy can be initiated with a full replacement dosage (1.6 micrograms/kg body weight), which is usually 75 to 100 micrograms/day for women and 100 to 150 micrograms/d for men. The goal is to normalize the serum thyroid-stimulating hormone concentration. Levothyroxine is also used to suppress the serum thyroid-stimulating hormone concentration. A trial of thyroid-stimulating hormone suppressive therapy is indicated for most patients with benign solitary nonfunctioning thyroid nodules and for those with a history of thyroid cancer. Levothyroxine in non-thyroid-stimulating hormone-suppressive doses may also be indicated for patients with nontoxic multinodular goiter and for certain patients after lobectomy for benign thyroid nodules. CONCLUSIONS: With proper patient monitoring, levothyroxine replacement therapy should be effective, inexpensive, and free of complications. Recommendations for thyroid-stimulating hormone suppression with levothyroxine are based on risk-benefit considerations of the biologic characteristics of the thyroid disorder and the individual patient.

Overview

Integrity signals

Registry

Crossref · 10.7326/0003-4819-119-6-199309150-00009

Cites

0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

The publisher hasn’t deposited this paper’s reference list.

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Mandel, S. J., Brent, G. A., & Larsen, P. R.
Affiliations
Brigham and Women's Hospital (US)
Corresponding author
Mandel, Susan J.
Venue
Annals of Internal Medicine
Publisher
American College of Physicians
Published
1993-09-15
Volume
119
Issue
6
Pages
492-502
ISSN
  • 0003-4819 (ISSN-L)
  • 1539-3704
DOI
10.7326/0003-4819-119-6-199309150-00009
OpenAlex
W2017578266
Cited by
324
References
0
Citations by year
2025: 2 · 2024: 4 · 2023: 8 · 2022: 4 · 2021: 11 · 2020: 9 · 2019: 5 · 2018: 6 · 2017: 9 · 2016: 15 · 2015: 12 · 2014: 13 · 2013: 16 · 2012: 14
FWCI
8.38
Type
journal article
Language
en
Open access
closed
Licence
www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
Locations
  • Annals of Internal Medicine (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (5r01dk043714-09)
  • National Institute of Diabetes and Digestive and Kidney Diseases (1 R01 DK 43714, R01DK036256, T32DK007529)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
  • Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
Keywords
levothyroxine, thyroid dysfunction, hypothyroidism, thyroid-stimulating hormone, TSH suppression therapy, thyroid hormone replacement, thyroid nodules, multinodular goiter, thyroid cancer, lobectomy, drug dosing, adverse effects
MeSH terms
Female, Humans, Male, Pituitary Gland, Thyroid Diseases, Thyroid Gland, Thyroid Hormones, Thyrotropin, Thyroxine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review